Clinical Trial Update: Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis [Phase 2]

View source ↗

Summary

Phase 2 study of miglustat (Zavesca) in patients with GM2 gangliosidosis assessed pharmacokinetics and tolerability; results describe PK parameters and tolerabi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gm2 Gangliosidosis

Drugs mentioned

• Zavesca (miglustat) (miglustat)

Snippet

Sponsor: The Hospital for Sick Children | Conditions: Gangliosidoses GM2 | Phase 2 | Status: COMPLETED